Drugs in ATC Class M01A

Up to Top Level ATC Classes

Up to M - Musculo-skeletal system

Up to M01 - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Subclasses in ATC: M01A - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

M01AA - Butylpyrazolidines

M01AB - Acetic acid derivatives and related substances

M01AC - Oxicams

M01AE - Propionic acid derivatives

M01AG - Fenamates

M01AH - Coxibs

M01AX - Other antiinflammatory and antirheumatic agents, non-steroids

M01A Market Analysis and Financial Projection

The ATC Class M01A (Antiinflammatory and Antirheumatic Products, Non-Steroids) represents a critical segment in global pharmaceuticals, driven by rising chronic pain prevalence and innovation in drug development. Below is a detailed analysis of its market dynamics and patent landscape:

---

Market Dynamics

1. Global Market Growth

   • The non-steroidal anti-inflammatory drugs (NSAIDs) market is projected to grow from $22.58 billion in 2024 to $31.29 billion by 2030 (CAGR: 5.66%)[3]. A competing estimate forecasts a rise from $15.58 billion in 2019 to $32.33 billion by 2032 (CAGR: 5.8%)[8].
   • Key drivers: Aging populations, chronic pain burden (arthritis, migraines), and regulatory shifts toward non-opioid analgesics[8][3].

2. Regional Insights

   • Middle East & Africa (MEA): Valued at $25 billion, led by Saudi Arabia ($8.2B) and Egypt, Algeria, and UAE (double-digit growth)[1]. Retail channels dominate (70% share), but institutional sales are rising (19% growth)[1].
   • North America: Holds 44% global market share (2019), driven by high prescription rates (84M NSAID scripts/year in the U.S.)[8].

3. Segmentation

   • Leading therapeutic areas: Arthritis accounts for 37.72% of sales (2024)[3].
   • Top players: Pfizer, Bayer, GSK, and Hikma Pharma (MEA leader with $215M sales)[1][3].

4. Competitive Landscape

   • Local/regional companies in MEA are gaining share (14% growth) over multinationals (7% growth)[1].
   • Generics dominate post-patent expiry (e.g., ibuprofen, naproxen sodium)[14][16].

---

Patent Landscape

1. Strategic Patenting Trends

   • Acquisition strategies: Companies like TOMTOM use patents to consolidate market positions (e.g., acquiring Applied Generics and Tele Atlas)[2].
   • Patent pools: Non-practicing entities (NPEs) monetize high-impact patents through litigation or licensing (e.g., Traffic Information LLC’s litigation targeting tech giants)[2][15].

2. Key Patents and Innovations

   • Combination therapies: Patents like US8580855B2 (acetaminophen/ibuprofen combinations) extend market exclusivity for pain relief[17].
   • White-space analysis: Focus on novel formulations (e.g., selective COX-2 inhibitors) to reduce gastrointestinal risks[8][12].

3. Geographic Patent Filings

   • China leads in AI-related patents, though U.S. and European entities like IBM and Google remain dominant in therapeutic innovations[9][11].
   • Patent cliffs: Expired patents for ibuprofen (11 U.S. patents) and naproxen sodium (6 U.S. patents) have enabled generic competition[14][16].

---

Challenges and Future Outlook

• Regulatory hurdles: Stricter safety requirements for NSAIDs (e.g., cardiovascular risks)[5][8].
• Generics competition: Post-2025, 80% of NSAID patents will expire, intensifying price pressures[14][16].
• Emerging opportunities: AI-driven drug discovery and sustainable manufacturing processes are key focus areas[9][15].

Key Insight: "Local pharmaceutical firms in MEA are outpacing multinationals, growing at 14% annually, driven by cost-effective generics and regional demand"[1].

---

Conclusion

The M01A market is poised for steady growth, shaped by aging demographics and innovation in combination therapies. However, patent expiries and generics will challenge incumbent players, while AI and strategic IP management will define future competitiveness.

References

1. https://www.iqvia.com/-/media/iqvia/pdfs/mea/edition-13-mea-pharmaceutical-market-quarterly-report.pdf
2. http://www.picmet.org/db/member/proceedings/2016/data/polopoly_fs/1.3251271.1472157441!/fileserver/file/680774/filename/16R0073.pdf
3. https://www.grandviewresearch.com/industry-analysis/non-steroidal-anti-inflammatory-drugs-market-report
4. https://www.degruyter.com/document/doi/10.1351/pac196919010049/pdf
5. https://atcddd.fhi.no/atc_ddd_index/?code=M01A
6. https://go.drugbank.com/drugs/DB00586
7. https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2019/belgian-reg-med-best-performers-for-january-2019.pdf?la=en&hash=7FD8BE058DD054FDAF3335C6D799C3D7
8. https://www.fortunebusinessinsights.com/non-steroidal-anti-inflammatory-drugs-nsaids-market-102823
9. https://www.sirris.be/en/inspiration/GenAI-patent-landscape
10. https://learn.microsoft.com/en-us/dynamics365/release-plan/2025wave1/smb/dynamics365-business-central/
11. https://www.patentnext.com/2022/05/artificial-intelligence-ai-patent-filings-continue-explosive-growth-trend-at-the-uspto/
12. https://www.bitlaw.com/source/pto/examples/43.html
13. https://patentpc.com/blog/ip-landscape-analysis
14. https://www.drugpatentwatch.com/p/generic-api/naproxen+sodium
15. https://www.lexisnexisip.com/resources/patent-landscape-analysis/
16. https://www.drugpatentwatch.com/p/generic/ibuprofen
17. https://patents.google.com/patent/US8580855B2/en